Notice: This company has been marked as potentially delisted and may not be actively trading. Harpoon Therapeutics (HARP) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Umoja Biopharma Appoints Scott Myers as Chairman of its Board of DirectorsNovember 21, 2024 | markets.businessinsider.comThe Harpoon Missile: A Great But Obsolete Weapon?October 20, 2024 | msn.comDaiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary EndpointSeptember 17, 2024 | marketwatch.comRay Therapeutics Appoints Christopher Whitmore as Chief Financial OfficerSeptember 16, 2024 | finance.yahoo.comAntibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLCSeptember 12, 2024 | msn.comMSK Team Identifies New Rare Small Cell Lung CancerSeptember 12, 2024 | msn.comT-cell targeting Candid Therapeutics launches with $370mSeptember 10, 2024 | finance.yahoo.comBig Pharma Stocks: Who’s Leading the Race and Who’s Slipping?August 22, 2024 | investing.comPharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other UpdatesAugust 9, 2024 | msn.comMerck to discontinue Phase 3 KeyVibe-008 trial based on recommendation of DMCAugust 8, 2024 | msn.comMerck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side EffectsAugust 8, 2024 | msn.comAmgen talks obesity drug ‘differentiation’; Servier brain cancer drug approved by FDAAugust 7, 2024 | finance.yahoo.comDaiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070August 7, 2024 | finance.yahoo.comShould You Pick Merck Stock At $115 After A Q2 Beat?August 1, 2024 | forbes.comMerck shares fall 9% despite earnings beat, strong demand for top drugs like KeytrudaJuly 31, 2024 | msn.comHarpoon Brewery And Life Is Good Want To Offer Fans A New Summer StyleMay 27, 2024 | forbes.comAmgen Drug Wins US Approval for Type of Advanced Lung CancerMay 16, 2024 | msn.comIs Johnson & Johnson Stock A Better Pick Over Merck?May 14, 2024 | forbes.comViracta Therapeutics Appoints Faerm As CFOMay 14, 2024 | markets.businessinsider.comMerck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.May 8, 2024 | msn.comMerck raises 2024 profit forecast on surging sales of cancer drug KeytrudaApril 25, 2024 | msn.comHARP Apr 2024 20.000 putMarch 16, 2024 | finance.yahoo.comHARP Sep 2024 20.000 putMarch 16, 2024 | finance.yahoo.comShort Interest in Harpoon Therapeutics, Inc. (NASDAQ:HARP) Declines By 53.6%Harpoon Therapeutics, Inc. (NASDAQ:HARP - Get Free Report) saw a significant drop in short interest in February. As of February 29th, there was short interest totalling 538,400 shares, a drop of 53.6% from the February 14th total of 1,160,000 shares. Approximately 4.3% of the company's shares are short sold. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is currently 0.5 days.March 13, 2024 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Merck & Company (MRK)March 13, 2024 | markets.businessinsider.comMerck completes acquisition of Harpoon TherapeuticsMarch 12, 2024 | msn.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Major Shareholder Buys $492,135,715.00 in StockMarch 12, 2024 | insidertrades.comMerck & Co., Inc. Acquires 21,397,205 Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP) StockHarpoon Therapeutics, Inc. (NASDAQ:HARP - Get Free Report) major shareholder Merck & Co., Inc. bought 21,397,205 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The shares were acquired at an average price of $23.00 per share, with a total value of $492,135,715.00. Following the purchase, the insider now owns 1,000 shares in the company, valued at $23,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.March 11, 2024 | marketbeat.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Position Lessened by Kennedy Capital Management LLCKennedy Capital Management LLC lowered its position in Harpoon Therapeutics, Inc. (NASDAQ:HARP - Free Report) by 90.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,987 shares of the company's stock after selling 476,9March 11, 2024 | marketbeat.comTrading was temporarily halted for "HARP" at 07:03 PM with a stated reason of "News pending."March 11, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)March 7, 2024 | markets.businessinsider.comHarpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to MerckMarch 6, 2024 | msn.comAcadian Asset Management LLC Sells 69,040 Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP)Acadian Asset Management LLC decreased its holdings in Harpoon Therapeutics, Inc. (NASDAQ:HARP - Free Report) by 90.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,670 shares of the company's stock after selling 69,040March 6, 2024 | marketbeat.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Shares Sold by MPM Bioimpact LLCMPM Bioimpact LLC lowered its position in shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP - Free Report) by 90.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 319,670 shares of the company's stock after selling 2,8March 1, 2024 | marketbeat.comCitigroup Downgrades Harpoon Therapeutics (HARP)February 27, 2024 | msn.comAnalyst Scoreboard: 4 Ratings For Harpoon TherapeuticsFebruary 26, 2024 | markets.businessinsider.comHarpoon Therapeutics (NASDAQ:HARP) Rating Reiterated by CitigroupCitigroup restated a "neutral" rating and issued a $23.00 price target (up from $13.00) on shares of Harpoon Therapeutics in a research note on Monday.February 26, 2024 | marketbeat.comHarpoon Therapeutics just downgraded at Citi, here's whyFebruary 24, 2024 | realmoney.thestreet.comFate of US Aid to Ukraine Package Discussed on Taiwan Trip, Lawmakers SayFebruary 23, 2024 | usnews.comMerck wins EU backing for Keytruda use in resectable lung cancerFebruary 23, 2024 | msn.comHARPOON THERAPEUTICS (5HTA.BE)February 23, 2024 | finance.yahoo.comHarpoon Therapeutics Inc. (5HTA.SG)February 23, 2024 | finance.yahoo.comStock (HARP), Short Interest ReportFebruary 22, 2024 | benzinga.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Short Interest Up 15.2% in JanuaryHarpoon Therapeutics, Inc. (NASDAQ:HARP - Get Free Report) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 547,700 shares, a growth of 15.2% from the January 15th total of 475,400 shares. Currently, 5.5% of the shares of the stock are short sold. Based on an average trading volume of 673,500 shares, the days-to-cover ratio is presently 0.8 days.February 17, 2024 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), 4D Molecular Therapeutics (FDMT)February 13, 2024 | markets.businessinsider.comMerck Hasn't Even Closed Its Last Buyout, But It's Already Hunting For The Next DealFebruary 1, 2024 | msn.comWhile private equity firms own 20% of Harpoon Therapeutics, Inc. (NASDAQ:HARP), retail investors are its largest shareholders with 36% ownershipJanuary 30, 2024 | finance.yahoo.comArix Bioscience PLC: Financial update on Harpoon Therapeutics acquisition by Merck (MSD)January 19, 2024 | finanznachrichten.deMerck, the Dow's hottest stock, gets set to report Q4 financials (HARP)Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks.January 18, 2024 | marketbeat.comPeeling Back The Layers: Exploring Harpoon Therapeutics Through Analyst InsightsJanuary 16, 2024 | markets.businessinsider.com Get Harpoon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter. Email Address Musk’s new company could top a trillion? (Ad)The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. HARP Media Mentions By Week HARP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HARP News Sentiment▼0.530.87▲Average Medical News Sentiment HARP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HARP Articles This Week▼01▲HARP Articles Average Week Get Harpoon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LIAN News PHXM News DRTSW News BCTXW News FBIOP News GOVXW News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HARP) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harpoon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harpoon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
